New Optimized Academic Anti-BCMA CAR therapy(Instituto de Biomedicina de Sevilla)

N/A

Report date: 2024/01/04 16:02:49

Base Information

Drug NameNew Optimized Academic Anti-BCMA CAR therapy(Instituto de Biomedicina de Sevilla)

Drug Alias NameCARTemis-1

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-BCMAT lymphocyte replacements

TargetsB-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesInstituto de Biomedicina de Sevilla

China Registration ClassN/A

Develop Information

Active CompaniesInstituto de Biomedicina de Sevilla

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A